Endotoxin removal

The Alteco LPS Adsorber contains discs made of porous polyethylene (PE) covered in a tailor-made peptide. The peptide binds to lipid A (the toxic part of endotoxin) with high affinity. By adsorbing harmful levels of endotoxin from the patient’s bloodstream, the Alteco LPS Adsorber can break the chain of immune system overreactions that can spiral into septic shock. This helps to stabilize the patient’s hemodynamic parameters in the acute situation.

Early treatment start

High levels of endotoxin activity are associated with organ failure and death. 1 For best treatment results, the Alteco LPS Adsorber should be used as early as possible. Hemoperfusion (HP) is the recommended treatment mode and allows treatment to start before acute kidney injury (AKI) escalates and the need for continuous renal replacement therapy (CRRT) arises.

Start treatment when the patient shows signs of imminent clinical deterioration, meaning:

  • Urine production is decreasing (acute kidney failure approaching)
  • Mean arterial pressure (MAP) ~ 65 mmHg
  • >2 hours of vasopressor support and patient still unstable

Treatment results and clinical benefits

Post treatment, patients usually demonstrate a reduction in endotoxin, procalcitonin and lactate levels, a reduction or elimination of vasopressor support, stability and improvement in hemodynamic parameters as well as SOFA score.

Removing the threat

Our mission is to safely help stabilize patients through extracorporeal endotoxin elimination.


Alteco Medical now has distributor agreements in place in Indonesia and Saudi Arabia.
Alteco Medical AB has entered into a distribution agreement with BTC Health, who is now appointed exclusive distributor for Alteco LPS Adsorber in Australia and New Zealand.
Alteco Medical has signed a distribution agreement with Incardia Biomedical Spa in Chile.
Alteco Medical has signed distribution contracts with new distributors in Panama and Iraq.
Alteco Medical has signed a contract with Medvision in Kuwait.
Alteco Medical welcomes distributors in Taiwan and Switzerland: Brojaw Inc. and Somapharm AG.
  1. John C. Marshall, et al; Diagnostic and Prognostic Implications of Endotoxemia in Critical Illness: Results of the MEDIC Study, The Journal of Infectious Diseases, Volume 190, Issue 3, 1 August 2004, Pages 527–534, https://doi.org/10.1086/422254